G'day Rojames, I am highly disappointed / annoyed as well. You have gone a step further and outlined what some of us must be thinking.
I was stunned in the recent Investor seminars at the lacklustre Exoma presentation. At stake was the EXE options being just out of the money and the important cap raising opportunity this represented. A stirring presentation performance was required, but it did not happen IMO. In fact I thought at the time (and mentioned in another thread) that it was surprising to hear it mentioned more than once "that it will be 18 months or so before this could be assessed to be a commercial venture" - may be honest, but hardly stirring stuff...
Again, I encourage SH to take the time and write to the company re our concerns.... surely the company should want to address SH fears about dilution & % of ownership is being rapidly stripped away ?
EXE Price at posting:
9.8¢ Sentiment: None Disclosure: Held
